Alinidine is a cardiovascular drug primarily used in the treatment of angina pectoris, heart failure, and myocardial infarction. It alleviates myocardial ischemia, improves cardiovascular function, and reduces myocardial oxygen consumption. It also modulates hemorheology, inhibits platelet aggregation and thrombosis, and exhibits lipid-lowering effects. Alinidine provides relief from high-altitude sickness. It significantly reduces total cholesterol, triglycerides, and low-density lipoprotein while increasing high-density lipoprotein in patients with coronary heart disease, thereby improving lipid metabolism and exerting anti-atherosclerotic effects. It markedly reduces blood hyperviscosity, improves hemorheological properties, accelerates blood flow, enhances microcirculation, and increases myocardial oxygen supply, effectively correcting the "myocardial stasis" condition. Additionally, it significantly enhances superoxide dismutase activity and protects myocardial tissue by inhibiting lipid peroxidation.